Insilico Medicine Ltd. has described protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.

Arcus Biosciences Inc. has divulged E3 ubiquitin-protein ligase CBL-B (CBLB) inhibitors reported to be useful for the treatment of cancer.

Ningbo Newbay Medical Technology Co. Ltd. has identified DNA polymerase θ (POLθ) inhibitors reported to be useful for the treatment of cancer.

Gan & Lee Pharmaceuticals Co. Ltd. has synthesized antibody-drug conjugates comprising a monoclonal antibody covalently linked to exatecan derivatives through a linker reported to be useful for the treatment of cancer.

Haihe Biopharma Co. Ltd. has disclosed benzo(hetero)cycloalkyl compounds reported to be useful for the treatment of acne, spinal and bulbar muscular atrophy, and more.

Biopolar Hongye (Nantong) Pharmaceutical Co., Ltd. has described proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase cereblon (CRBN) binding moiety covalently linked to a Bruton’s tyrosine kinase (BTK) binding moiety reported to be useful for the treatment of cancer, inflammatory and autoimmune diseases.

Deciphera Pharmaceuticals LLC has divulged eukaryotic translation initiation factor 2-α kinase 3 (PERK) and/or GCN2 inhibitors reported to be useful for the treatment of cancer and amyloidosis.

Solve Therapeutics Inc. has identified antibody-drug conjugates comprising an UC-961 antibody or a tyrosine-protein kinase transmembrane receptor ROR2 (ROR2)-targeting antibody covalently linked to exatecan through a linker reported to be useful for the treatment of cancer.

Ryvu Therapeutics SA has synthesized protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.

DM Intelligence Medicine Ltd. has disclosed leucine-rich repeat kinase 2 (LRRK2; dardarin), LRRK2 (G2019S mutant) and/or EGFR (HER1; erbB1 mutant) inhibitors reported to be useful for the treatment of cancer, neurological and immunological disorders.